The effectiveness of single-dose intravenous oritavancin was similar to that of seven- to 10-day treatment with intravenous vancomycin for acute bacterial skin and skin structure infections, a multicenter study found. The most common adverse events reported in the oritavancin group included nausea, diarrhea and headache. Oritavancin was "well-tolerated, with a safety profile similar to vancomycin," lead author Dr. G. Ralph Corey reported at the Interscience Conference on Antimicrobial Agents and Chemotherapy.
Oritavancin compared against vancomycin for skin infections
SmartBrief Job Listings for Health Care
|Chief Financial Officer||
B. E. Smith
Attest Health Care Advisors
|Biotechnology/Pharmaceutical Patent Attorney||
Coats and Bennett PLLC
|Sr. Regulatory Specialist, Biotech Center of Expertise||
BASF, The Chemical Co.
|San Diego, CA|